Google
Trusted Resources: Community Center
Online support, community stories, financial assistance
Ionis Pharmaceuticals, Inc. – Linkedin
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, proprietary antisense technology platform with the potential to treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs – such as children and adults with spinal muscular atrophy (SMA).
Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 drugs with the potential to treat patients with cardiovascular disease, rare diseases, neurological diseases, infectious diseases and cancer. We created TEGSEDI™ (inotersen) the world’s first RNA-targeted therapeutic approved for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin (TTR) amyloidosis (ATTR) that our affiliate Akcea Therapeutics is commercializing.
myBinderRelated Content
-
North Carolina – Amyloidosis Support Groups Meeting – LIVE – Saturday, September 30, 2023When: Saturday, September 30, 2023 | 9...
-
Myeloma UKMyeloma UK is the only organization in t...
-
ALect2 AllianceALect2 Alliance is a nonprofit group rai...
-
On-Demand COVID-19 Preparedness WebinarThis discussion was recorded on March ...
-
Hereditary Amyloidosis CanadaThe Hereditary Amyloidosis Canada (HAC) ...
-
Amyloidosis Foundation Patient Webinar, “Amyloidosis 101”https://www.youtube.com/watch?v=FBdQrgbH...
-
Anne Marie CarrMy name is Anne Marie Carr and I was dia...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
